126 related articles for article (PubMed ID: 34548162)
1. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Wenzel L; Huang HQ; Cella D; McKinney CO; Zevon MA; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; von Gruenigen VE
Gynecol Oncol; 2021 Nov; 163(2):392-397. PubMed ID: 34548162
[TBL] [Abstract][Full Text] [Related]
2. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
von Gruenigen VE; Huang HQ; Cella D; Zevon M; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; Wenzel L
Gynecol Oncol; 2018 Jul; 150(1):119-126. PubMed ID: 29778506
[TBL] [Abstract][Full Text] [Related]
3. Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
Trigg A; Kelly M; Iadeluca L; Chang J; Moreno-Koehler A; Yaworsky A; Krohe M; Rider A; Cappelleri JC; Cella D; Cocks K
Future Oncol; 2021 Oct; 17(30):3951-3964. PubMed ID: 34287020
[TBL] [Abstract][Full Text] [Related]
4. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Peipert JD; Goble S; Isaacson J; Tang X; Wallace K; Coleman RL; Ledermann JA; Cella D
Gynecol Oncol; 2023 Aug; 175():1-7. PubMed ID: 37262961
[TBL] [Abstract][Full Text] [Related]
6. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
Phippen NT; Secord AA; Wolf S; Samsa G; Davidson B; Abernethy AP; Cella D; Havrilesky LJ; Burger RA; Monk BJ; Leath CA
Gynecol Oncol; 2017 Oct; 147(1):98-103. PubMed ID: 28743369
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
10. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.
Beesley VL; Green AC; Wyld DK; O'Rourke P; Wockner LF; deFazio A; Butow PN; Price MA; Horwood KR; Clavarino AM; Australian Ovarian Cancer Study Group ; Australian Ovarian Cancer Study-Quality Of Life Study Investigators ; Webb PM
Gynecol Oncol; 2014 Jan; 132(1):130-6. PubMed ID: 24125750
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Lee M; Lee Y; Kim K; Park EY; Lim MC; Kim JS; Kim HS; Kim YB; Kim YM; Joo J; Park SY; Choi CH; Kim JH
Cancer Res Treat; 2019 Jan; 51(1):112-118. PubMed ID: 29510610
[TBL] [Abstract][Full Text] [Related]
13. A new index of priority symptoms in advanced ovarian cancer.
Jensen SE; Rosenbloom SK; Beaumont JL; Abernethy A; Jacobsen PB; Syrjala K; Cella D
Gynecol Oncol; 2011 Feb; 120(2):214-9. PubMed ID: 21075440
[TBL] [Abstract][Full Text] [Related]
14. Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials.
Shaunfield S; Jensen S; Fisher AP; Webster K; Shahabi S; Ganguli A; Cella D
Health Qual Life Outcomes; 2019 Dec; 17(1):185. PubMed ID: 31856850
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
16. The comparison of functional status and health-related parameters in ovarian cancer survivors with healthy controls.
Gultekin SC; Cakir AB; Guc ZG; Ozalp FR; Keskinkilic M; Yavuzsen T; Yavuzsen HT; Karadibak D
Support Care Cancer; 2024 Jan; 32(2):119. PubMed ID: 38252310
[TBL] [Abstract][Full Text] [Related]
17. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P
Lancet Oncol; 2021 May; 22(5):632-642. PubMed ID: 33862001
[TBL] [Abstract][Full Text] [Related]
18. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
Campbell R; King MT; Ross TL; Cohen PA; Friedlander ML; Webb PM
Gynecol Oncol; 2021 Nov; 163(2):398-407. PubMed ID: 34481610
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]